In this article
A major clinical trial has found that a single dose of an LSD-derived compound, known as MM120 (lysergide D-tartrate), can significantly reduce symptoms of chronic anxiety for weeks after treatment. Conducted by researchers at the University of California, San Francisco (UCSF) and collaborating centers, this breakthrough may redefine how chronic anxiety is treated, offering an alternative for millions of people who remain resistant to standard therapies.
What the study found
Chronic anxiety, often diagnosed as Generalized Anxiety Disorder (GAD), affects a large portion of adults worldwide. It is marked by excessive and uncontrollable worry that interferes with sleep, focus, and quality of life. Common treatments such as SSRIs and SNRIs help some patients, but nearly half fail to achieve lasting relief.
In this randomized, double-blind, placebo-controlled phase 2b study, nearly 200 adults with moderate-to-severe chronic anxiety received a single oral dose of MM120 in one of four concentrations (25 µg, 50 µg, 100 µg, or 200 µg) or a placebo. The main outcome measured was the change in the Hamilton Anxiety Rating Scale (HAM-A) after four weeks, with additional assessments continuing through twelve weeks.
Participants who received 100 µg and 200 µg doses showed the strongest improvement compared to placebo, with reductions of 7.6 points greater on the HAM-A scale at week four. By week twelve, about 65 percent of participants had a clinical response and nearly half had achieved full remission. Reported side effects were consistent with other psychedelics and included temporary visual changes, nausea, and mild headaches, but no serious safety issues.
Why this matters for mental health treatment
This is one of the first modern studies to demonstrate that a psychedelic-inspired compound can produce measurable, lasting relief for chronic anxiety after a single administration and without psychotherapy support.
For decades, anxiety research has focused on chronic daily medications that often take weeks to show benefits and can cause side effects or dependency. MM120 offers a different approach: a single, fast-acting intervention that may deliver sustained effects by addressing the underlying neural rigidity associated with anxiety.
The findings suggest that the brain’s default patterns of worry and fear can be temporarily “reset,” providing a window for new, healthier cognitive processes to form.
Mechanism and theoretical implications
MM120 is a pharmaceutical-grade formulation of LSD engineered for controlled medical use. Scientists believe its mechanism of action involves increasing neuroplasticity and improving communication between brain regions that regulate emotion and self-awareness.
In individuals with chronic anxiety, overactive neural loops in the amygdala and prefrontal cortex tend to reinforce repetitive thought patterns. By enhancing connectivity and flexibility in these networks, MM120 may interrupt these cycles and restore balanced emotional processing. The fact that one dose produced multi-week relief supports the theory that psychedelics can create short but powerful therapeutic windows, reducing the need for long-term daily dosing.
Broader implications for mental health research
The MM120 results highlight a growing recognition that psychedelic-derived compounds may hold genuine therapeutic value for chronic anxiety. The ability of a single, precisely dosed compound to deliver sustained symptom relief could signal a major shift in psychiatric treatment models, moving beyond daily maintenance medications toward more targeted, episodic interventions.
These findings also strengthen the scientific understanding of how psychedelics affect the brain. By enhancing neuroplasticity and temporarily increasing communication between neural networks involved in mood regulation, MM120 appears to interrupt the repetitive cognitive patterns that define chronic anxiety. Continued investigation may reveal whether similar mechanisms could benefit related conditions such as depression, PTSD, or obsessive-compulsive disorder.
Limitations and caveats
While the results are highly promising, several limitations remain:
- The study is phase 2b and requires confirmation through larger phase 3 trials.
- Participants were treated in controlled environments, which may differ from real-world conditions.
- Temporary perceptual effects were common at higher doses, emphasizing the need for medical supervision.
- Long-term safety data beyond twelve weeks are still limited.
- The role of psychological integration or therapy in maintaining outcomes has yet to be studied.
What comes next
MindMed Inc., the company behind MM120, is now launching phase 3 clinical trials to further test its effectiveness in chronic anxiety and major depressive disorder. If confirmed, MM120 could become the first LSD-based prescription medication approved for anxiety disorders, representing a major advancement in psychiatric care.
Conclusion
The MM120 trial marks a significant turning point in the treatment of chronic anxiety. It shows that a single, carefully administered psychedelic compound can provide lasting symptom relief without daily dependence on medication.
If future studies uphold these findings, LSD derivatives like MM120 could reshape how chronic anxiety is managed, merging precision neuroscience with a deeper understanding of the brain’s capacity for change. For patients living with unrelenting anxiety, this research offers something rare, credible hope for lasting calm. 
